FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2623181623> ?p ?o ?g. }

• W2623181623 endingPage "75" @default.
• W2623181623 startingPage "69" @default.
• W2623181623 abstract "Currently 18F-2-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography/computerized tomography (PET/CT) is being successfully used for staging and follow-up of Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). Various studies have demonstrated that PET/CT effectively detects bone marrow involvement (BMI) and is concordant with bone marrow biopsy (BMB) findings, thus it is deemed as a complementary method. This study was aimed to evaluate18F-FDG-PET/CT efficiency for detection of BMI in HL and NHL.The study included 172 lymphoma cases who were admitted to Akdeniz University Medical School Department of Nuclear Medicine for initial staging with PET/CT. Visual and semiquantitative assessments were performed for PET/CT scan findings of the cases. The maximum standard uptake (SUVmax) value was the quantitative parameter used for 18F-FDG-PET scan. In visual assessment, bone marrow metabolic activity that is greater than the liver was considered as pathologic. For semiquantitative assessment, regions of interest were drawn for SUVmax estimation, which included iliac crest in cases with diffusely increased metabolic activity and the highest activity area in cases with focal involvement. BMB was considered as the reference test.On visual assessment of all the cases, PET/CT was found to yield 31% sensitivity and 85% specificity rate for detection of BMI. On visual assessment of HL cases, sensitivity rate was determined as 80%, and specificity as 78%, while in NHL cases the corresponding values were 24% and 90%, respectively. On semiquantitative assessment of HL cases, considering SUVmax≥4, sensitivity was found as 80% and specificity as 68%. In NHL patients, considering SUVmax≥3.2, sensitivity rate was detected as 65% and specificity as 58%.In this study, a moderately high concordance was observed between PET/CT and BMB findings. PET/CT appears to be a significant method for detecting BMI. Although PET/CT is not a substitute for BMB, we suggest it can be used as a guide to biopsy site and a complementary imaging technique for BMB.Amaç: Günümüzde 18F-2-fluoro-2-deoksi-D-glukoz (18F-FDG) pozitron emisyon tomografisi/bilgisayarlı tomografi (PET/BT), Hodgkin lenfoma (HL) ve non-Hodgkin lenfomaların (NHL) evrelemesinde ve takibinde başarılı bir şekilde kullanılmaktadır. Değişik çalışmalarda PET/BT’nin kemik iliği tutulumunu göstermede etkinliği ve kemik iliği biyopsisi (KİB) ile uyumu gösterilmiş ve tamamlayıcı yöntem olarak kullanılması önerilmiştir. Biz de bu çalışmada HL ve NHL’de kemik iliği infiltrasyonunu değerlendirmede PET/BT’nin etkinliğini değerlendirmeyi amaçladık. Yöntem: Çalışmaya Akdeniz Üniversitesi Tıp Fakültesi Nükleer Tıp Anabilim Dalı’nda başlangıç evreleme için PET/BT tetkiki yapılan 172 lenfoma olgusu dahil edilmiştir. Olguların PET/BT tetkikinde görsel ve semikantitatif değerlendirme yapıldı.18F-FDG-PET tetkikinde kantitatif parametre olarak maksimum standart uptake değeri (SUVmaks) kullanıldı. Görsel değerlendirmede karaciğerden daha yüksek metabolik aktivite gösteren kemik iliği aktivitesi patolojik olarak değerlendirildi. Semikantitatif değerlendirmede ise kemik iliğinde diffüz metabolik aktivite artışı gösteren olgularda iliak kanattan, fokal tutulumda ise en yüksek aktivite gösteren alandan ilgi alanı çizdirilerek SUVmaks değeri hesaplandı. KİB sonuçları referans olarak alınmıştır. Bulgular: Tüm olgular için görsel değerlendirmede PET/BT’nin kemik iliği infiltrasyonunu göstermede duyarlılığı %31, özgüllüğü %85 olarak saptanmıştır. HL olgularında görsel değerlendirmede duyarlılık %80, özgüllük %78; NHL olgularında ise duyarlılık %24, özgüllük %90 olarak bulunmuştur. Semikantitatif değerlendirmede HL’de SUVmaks≥4 alındığında duyarlılık %80, özgüllük %68 olarak saptanmıştır. NHL’de ise SUVmaks≥3,2 olarak belirlendiğinde duyarlılık %65, özgüllük %58 olarak bulunmuştur. Sonuç: Bu çalışmada, çok yüksek olmamakla birlikte, PET/BT bulguları ile KİB sonuçları arasında uyum izlendi. PET/BT görüntülemenin kemik iliği infiltrasyonu olup olmadığını göstermede etkili bir yöntem olduğunu görmekteyiz. PET/BT’nin, KİB’nin yerini almamakla birlikte, biyopsi yapılabilecek bölgeyi göstermede yönlendirici ve KİB’yi tamamlayıcı bir görüntüleme yöntemi olarak kullanılabileceğini düşünmekteyiz." @default.
• W2623181623 created "2017-06-15" @default.
• W2623181623 creator A5005763321 @default.
• W2623181623 creator A5007578242 @default.
• W2623181623 creator A5018736306 @default.
• W2623181623 creator A5019334532 @default.
• W2623181623 creator A5025115833 @default.
• W2623181623 creator A5053736646 @default.
• W2623181623 creator A5070606480 @default.
• W2623181623 creator A5077954387 @default.
• W2623181623 creator A5084510032 @default.
• W2623181623 creator A5086328341 @default.
• W2623181623 creator A5087112104 @default.
• W2623181623 date "2017-06-07" @default.
• W2623181623 modified "2023-10-17" @default.
• W2623181623 title "Efficacy of 18F-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography/Computerized Tomography for Bone Marrow Infiltration Assessment in the Initial Staging of Lymphoma" @default.
• W2623181623 cites W139830920 @default.
• W2623181623 cites W1862208033 @default.
• W2623181623 cites W1963045338 @default.
• W2623181623 cites W1968893796 @default.
• W2623181623 cites W1972559145 @default.
• W2623181623 cites W1972918840 @default.
• W2623181623 cites W1992575374 @default.
• W2623181623 cites W2003856347 @default.
• W2623181623 cites W2007477916 @default.
• W2623181623 cites W2012324903 @default.
• W2623181623 cites W2030862923 @default.
• W2623181623 cites W2033256368 @default.
• W2623181623 cites W2035448191 @default.
• W2623181623 cites W2043867257 @default.
• W2623181623 cites W2060883642 @default.
• W2623181623 cites W2078437020 @default.
• W2623181623 cites W2111544864 @default.
• W2623181623 cites W2121638592 @default.
• W2623181623 cites W2169407833 @default.
• W2623181623 cites W72510416 @default.
• W2623181623 doi "https://doi.org/10.4274/mirt.54376" @default.
• W2623181623 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5472089" @default.
• W2623181623 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28613199" @default.
• W2623181623 hasPublicationYear "2017" @default.
• W2623181623 type Work @default.
• W2623181623 sameAs 2623181623 @default.
• W2623181623 citedByCount "7" @default.
• W2623181623 countsByYear W26231816232019 @default.
• W2623181623 countsByYear W26231816232020 @default.
• W2623181623 countsByYear W26231816232021 @default.
• W2623181623 countsByYear W26231816232022 @default.
• W2623181623 countsByYear W26231816232023 @default.
• W2623181623 crossrefType "journal-article" @default.
• W2623181623 hasAuthorship W2623181623A5005763321 @default.
• W2623181623 hasAuthorship W2623181623A5007578242 @default.
• W2623181623 hasAuthorship W2623181623A5018736306 @default.
• W2623181623 hasAuthorship W2623181623A5019334532 @default.
• W2623181623 hasAuthorship W2623181623A5025115833 @default.
• W2623181623 hasAuthorship W2623181623A5053736646 @default.
• W2623181623 hasAuthorship W2623181623A5070606480 @default.
• W2623181623 hasAuthorship W2623181623A5077954387 @default.
• W2623181623 hasAuthorship W2623181623A5084510032 @default.
• W2623181623 hasAuthorship W2623181623A5086328341 @default.
• W2623181623 hasAuthorship W2623181623A5087112104 @default.
• W2623181623 hasBestOaLocation W26231816231 @default.
• W2623181623 hasConcept C126838900 @default.
• W2623181623 hasConcept C141071460 @default.
• W2623181623 hasConcept C142724271 @default.
• W2623181623 hasConcept C163716698 @default.
• W2623181623 hasConcept C2775842073 @default.
• W2623181623 hasConcept C2775934546 @default.
• W2623181623 hasConcept C2779079599 @default.
• W2623181623 hasConcept C2779338263 @default.
• W2623181623 hasConcept C2780007613 @default.
• W2623181623 hasConcept C2989005 @default.
• W2623181623 hasConcept C71924100 @default.
• W2623181623 hasConceptScore W2623181623C126838900 @default.
• W2623181623 hasConceptScore W2623181623C141071460 @default.
• W2623181623 hasConceptScore W2623181623C142724271 @default.
• W2623181623 hasConceptScore W2623181623C163716698 @default.
• W2623181623 hasConceptScore W2623181623C2775842073 @default.
• W2623181623 hasConceptScore W2623181623C2775934546 @default.
• W2623181623 hasConceptScore W2623181623C2779079599 @default.
• W2623181623 hasConceptScore W2623181623C2779338263 @default.
• W2623181623 hasConceptScore W2623181623C2780007613 @default.
• W2623181623 hasConceptScore W2623181623C2989005 @default.
• W2623181623 hasConceptScore W2623181623C71924100 @default.
• W2623181623 hasIssue "2" @default.
• W2623181623 hasLocation W26231816231 @default.
• W2623181623 hasLocation W26231816232 @default.
• W2623181623 hasLocation W26231816233 @default.
• W2623181623 hasLocation W26231816234 @default.
• W2623181623 hasOpenAccess W2623181623 @default.
• W2623181623 hasPrimaryLocation W26231816231 @default.
• W2623181623 hasRelatedWork W1850966495 @default.
• W2623181623 hasRelatedWork W2011871178 @default.
• W2623181623 hasRelatedWork W201778226 @default.
• W2623181623 hasRelatedWork W2035448191 @default.
• W2623181623 hasRelatedWork W2042857088 @default.
• W2623181623 hasRelatedWork W3021952287 @default.
• W2623181623 hasRelatedWork W3029323126 @default.
• W2623181623 hasRelatedWork W3158680495 @default.

• next